Hello and welcome to the Psychiatry and Psychothermic Podcast.

I'm here to talk about getting rid of burnout, increasing job satisfaction, and feeling

like an expert in what you do.

One thing that created a lot of burnout and angst for me was trying to get continued medical

education right at the last minute.

So why not join the CME membership and do CME while listening to this podcast?

Go to Psychiatrypodcast.com, sign up, sign in, take the test, and the certification

is emailed to you in seconds.

Before I begin the episode, I wanted to give a brief introduction.

Alzheimer's disease is a devastating, neurodegenerative condition that affects the entire family.

As psychiatrists and psychologists, we often support these patients and their families

throughout the entire disease process.

With recent and controversial FDA approval of ADU CAN UMAB, a new pharmacotherapy for Alzheimer's

disease, we can expect to be asked about this drug from our patients and their family.

Initially, there was a lot of excitement from the scientific community when ADU CAN UMAB

and other similar pharmacotherapies first entered clinical trials.

However, Phase III clinical trial of several drugs in this class failed to show clinical

improvement in memory and cognitive functions, despite their high efficacy in removing

CNS amyloid plaques and the classic brain pathology of Alzheimer's disease.

Therefore, it was a surprise to many scientists and clinicians when the FDA officially approved

ADU CAN UMAB on June 7, 2021.

When we took a deep dive into the controversy, our findings were shocking.

...